- |||||||||| dexamethasone / Generic mfg., bendamustine / Generic mfg., pomalidomide / Generic mfg.
Trial completion date: Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma (clinicaltrials.gov) - Feb 20, 2024 P1/2, N=56, Active, not recruiting, Phase classification: P1/2 --> P1 Trial completion date: Jan 2023 --> Jan 2025
- |||||||||| bortezomib / Generic mfg., dexamethasone / Generic mfg., cytarabine / Generic mfg.
Trial completion, Enrollment change, Trial completion date: Trial of Bortezomib, Cytarabine, and Dexamethasone in Mantle Cell Lymphoma (clinicaltrials.gov) - Mar 20, 2023 P2, N=19, Completed, Terminated --> Completed Recruiting --> Completed | N=32 --> 19 | Trial completion date: Jun 2025 --> Dec 2022
- |||||||||| lenalidomide / Generic mfg.
Trial completion, Trial completion date: IFM2005-02: Maintenance Therapy Using Lenalidomide in Myeloma (clinicaltrials.gov) - Apr 26, 2019 P3, N=614, Completed, Completed --> Terminated; Terminated due to poor accrual Active, not recruiting --> Completed | Trial completion date: Sep 2020 --> Sep 2018
- |||||||||| Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial completion: Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma (clinicaltrials.gov) - Apr 20, 2019 P2, N=21, Completed, Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| bortezomib / Generic mfg.
Trial completion: Bortezomib Consolidation Trial (clinicaltrials.gov) - Apr 20, 2019 P2, N=40, Completed, Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| bortezomib / Generic mfg., dexamethasone / Generic mfg., lenalidomide / Generic mfg.
Trial completion, Trial completion date, Trial primary completion date: IFM/DFCI2009: Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years (clinicaltrials.gov) - Apr 20, 2019 P3, N=700, Completed, Active, not recruiting --> Completed | Trial primary completion date: Oct 2018 --> Mar 2019 Active, not recruiting --> Completed | Trial completion date: Sep 2020 --> Nov 2018 | Trial primary completion date: Sep 2018 --> Nov 2018
- |||||||||| Grafalon (rabbit anti-T-lymphocyte globulin) / Mundipharma, NeoPharm
Trial completion: Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD) (clinicaltrials.gov) - Apr 20, 2019 P3, N=260, Completed, Completed --> Terminated; The study was closed by the Sponsor according to the protocol-specified minimum post-treatment follow-up period of 3 years. Active, not recruiting --> Completed
- |||||||||| Trial completion, Trial completion date, Trial primary completion date: Lipoprotein Lipase Expression in Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Apr 20, 2019
P=N/A, N=29, Completed, Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> May 2018 | Trial primary completion date: Dec 2018 --> May 2018
- |||||||||| bortezomib / Generic mfg.
Trial completion: Autophagy Induction After Bortezomib for Myeloma (clinicaltrials.gov) - Apr 20, 2019 P1, N=11, Completed, Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> May 2018 | Trial primary completion date: Dec 2018 --> May 2018 Active, not recruiting --> Completed
- |||||||||| melphalan / Generic mfg., carfilzomib / Generic mfg., bendamustine / Generic mfg.
Trial completion, Enrollment change: Phase I: Melphalan, Bendamustine and Carfilzomib for Autologous Transplant in Multiple Myeloma (clinicaltrials.gov) - Apr 19, 2019 P1, N=18, Completed, Active, not recruiting --> Completed | Trial completion date: Dec 2017 --> Jun 2018 Active, not recruiting --> Completed | N=26 --> 18
- |||||||||| busulfan / Generic mfg.
Biomarker, Trial completion date, Trial primary completion date: ALL SCTped FORUM - Pharmacogenomic Study (add-on Study) (clinicaltrials.gov) - Apr 16, 2019 P4, N=1000, Recruiting, Completed --> Terminated Trial completion date: Apr 2023 --> Apr 2026 | Trial primary completion date: Apr 2018 --> Apr 2021
- |||||||||| Zydelig (idelalisib) / Gilead, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Enrollment change, Trial withdrawal: Clonal Evolution of B Cells in High-risk CLL After Idelalisib-rituximab (clinicaltrials.gov) - Apr 16, 2019 P=N/A, N=0, Withdrawn, Trial completion date: Apr 2023 --> Apr 2026 | Trial primary completion date: Apr 2018 --> Apr 2021 N=20 --> 0 | Recruiting --> Withdrawn
- |||||||||| Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Metastases: CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice (clinicaltrials.gov) - Apr 2, 2019
P=N/A, N=23, Terminated, N=20 --> 0 | Recruiting --> Withdrawn N=100000 --> 23 | Trial completion date: Oct 2019 --> Mar 2019 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2019 --> Mar 2019; Registry was built to handle Medicare coverage decision on NGS, but CMS decided to not require data.
- |||||||||| zilovertamab (UC-961) / Oncternal Therap
Trial completion, Trial completion date, Trial primary completion date: Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961 (clinicaltrials.gov) - Mar 20, 2019 P1, N=3, Completed, N=100000 --> 23 | Trial completion date: Oct 2019 --> Mar 2019 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2019 --> Mar 2019; Registry was built to handle Medicare coverage decision on NGS, but CMS decided to not require data. Active, not recruiting --> Completed | Trial completion date: Sep 2022 --> May 2018 | Trial primary completion date: Sep 2021 --> Feb 2018
- |||||||||| bortezomib / Generic mfg.
Trial completion, Enrollment change: Evaluation of Cardiotoxic Effects of Bortezomib (clinicaltrials.gov) - Mar 14, 2019 P=N/A, N=11, Completed, Active, not recruiting --> Terminated; lack of recruitment Not yet recruiting --> Completed | N=20 --> 11
- |||||||||| Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab, Arzerra (ofatumumab) / Novartis, Genmab
Trial completion, Trial completion date: Study of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Mar 5, 2019 P1/2, N=46, Completed, Completed --> Terminated; The study was terminated by the Sponsor for administrative reasons and not due to any safety concerns. Active, not recruiting --> Completed | Trial completion date: Jan 2020 --> Jan 2018
- |||||||||| Campath (alemtuzumab) / Sanofi, Neupogen (filgrastim) / Kyowa Kirin, Amgen, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial completion: Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System (clinicaltrials.gov) - Mar 5, 2019 P2, N=92, Completed, Active, not recruiting --> Completed | Trial completion date: Jan 2020 --> Jan 2018 Active, not recruiting --> Completed
- |||||||||| Cyramza (ramucirumab) / Eli Lilly
Trial completion, Enrollment change, Trial completion date, Combination therapy, Metastases: A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents (clinicaltrials.gov) - Mar 5, 2019 P1a/1b, N=23, Completed, Active, not recruiting --> Completed Active, not recruiting --> Completed | N=45 --> 23 | Trial completion date: May 2019 --> Jan 2019
- |||||||||| Campath (alemtuzumab) / Sanofi
Trial completion, Enrollment change, Trial primary completion date, Combination therapy, IO biomarker: ACT-1: Alemtuzumab and CHOP in T-cell Lymphoma (clinicaltrials.gov) - Mar 1, 2019 P3, N=136, Completed, Active, not recruiting --> Completed Active, not recruiting --> Completed | N=308 --> 136 | Trial primary completion date: Apr 2015 --> Dec 2016
- |||||||||| Trial completion, Trial completion date, Combination therapy: ACVDL Treatment for Patients With Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - Mar 1, 2019
P2, N=35, Completed, Active, not recruiting --> Completed | N=308 --> 136 | Trial primary completion date: Apr 2015 --> Dec 2016 Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> Aug 2018
- |||||||||| Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca, danvatirsen (AZD9150) / AstraZeneca, Flamingo Therapeutics
Trial completion, Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, PD(L)-1 Biomarker, IO biomarker: MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023) (clinicaltrials.gov) - Feb 27, 2019 P1b, N=32, Completed, Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Nov 2023 --> Feb 2019 | Trial primary completion date: Nov 2023 --> Feb 2019
- |||||||||| Enrollment closed, Phase classification: A Study for Older Adults With Acute Lymphoblastic Leukaemia (clinicaltrials.gov) - Feb 15, 2019
P2, N=126, Active, not recruiting, Active, not recruiting --> Completed | Trial completion date: Nov 2019 --> Aug 2017 Recruiting --> Active, not recruiting | Phase classification: P3 --> P2
- |||||||||| Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Enrollment change: ICLL-07: Phase II Trial GA101 Inbrutinib B CLL (clinicaltrials.gov) - Feb 15, 2019 P2, N=135, Completed, Recruiting --> Active, not recruiting | Phase classification: P3 --> P2 N=12 --> 135
|